VcMMAE
VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc) .
Product Specifications
CAS Number
646502-53-6
Product Name Alternative
MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE; Vedotin
UNSPSC
12352203
Hazard Statement
H300+H330, H340, H360, H370, H372, H412
Target
Drug-Linker Conjugates for ADC; Microtubule/Tubulin
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/VcMMAE.html
Purity
99.98
Solubility
DMSO : ≥ 54 mg/mL|Ethanol : 50 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
Molecular Formula
C68H105N11O15
Molecular Weight
1316.63
Precautions
H300+H330, H340, H360, H370, H372, H412
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture and light)
Scientific Category
ADC Related
Clinical Information
No Development Reported
Isoform
Auristatin
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Lentiviral human KAT2B sgRNA gene knockout kit - Lentiviral human KAT2B sgRNA gene knockout kit (25)
